Effects of Hydrocodone Rescheduling on Pain Management Practices Among Older Breast Cancer Patients
Open Access
- 23 October 2025
- journal article
- research article
- Published by MDPI AG in Current Oncology
- Vol. 32 (11) , 593
Abstract
Hydrocodone, a commonly prescribed opioid, was rescheduled from Schedule III to Schedule II in October 2014, imposing stricter prescribing regulations. While prior studies have examined its effects in general populations, its impact on breast cancer patients remains unclear. We evaluated changes in pain management among older women with early-stage breast cancer following this policy change. Using SEER-Medicare data from 2011–2019, we identified a retrospective cohort of 52,792 women aged ≥66 years. We assessed trends in the use of hydrocodone, non-hydrocodone opioids, NSAIDs, and antidepressants before and after rescheduling. Hydrocodone use declined from 55% to 40%, while non-hydrocodone opioid use increased from 43% to 50%. Multivariable logistic regression adjusted for demographic and clinical factors confirmed a significant decrease in hydrocodone use (AOR: 0.81, 95% CI: 0.75–0.86) and an increase in non-hydrocodone opioid use (AOR: 1.25, 95% CI: 1.21–1.30). Hydrocodone dosage also declined, while non-hydrocodone opioid dosages remained stable. No significant changes were observed in NSAID or antidepressant use. These findings suggest that hydrocodone rescheduling significantly altered opioid prescribing patterns, reducing hydrocodone use and prompting a shift toward alternative opioids. Further research is warranted to evaluate the appropriateness and outcomes of such shifts in cancer pain management.Keywords
Funding Information
- National Institutes of Health (R21 CA277849.)
This publication has 42 references indexed in Scilit:
- Association between pain medication misuse, psychological distress, and opioid use disorder among adults with lifetime cancer diagnosis in the United StatesSupportive Care in Cancer, 2025
- Long-Term Use of Muscle Relaxant Medications for Chronic PainJAMA Network Open, 2024
- The impact of hydrocodone rescheduling on utilization, abuse, misuse, and overdose deathsPharmacoepidemiology and Drug Safety, 2023
- Assessment of Physician Prescribing of Muscle Relaxants in the United States, 2005-2016JAMA Network Open, 2020
- A Clinical Overview of Off-label Use of Gabapentinoid DrugsJAMA Internal Medicine, 2019
- Misuse of prescribed opioids in the United StatesPharmacoepidemiology and Drug Safety, 2019
- Association of Hydrocodone Schedule Change With Opioid Prescriptions Following SurgeryJAMA Surgery, 2018
- Using trajectory models to assess the effect of hydrocodone upscheduling among chronic hydrocodone usersPharmacoepidemiology and Drug Safety, 2018
- Decline in opioid prescribing after federal rescheduling of hydrocodone productsPharmacoepidemiology and Drug Safety, 2017
- Risk factors of pain in breast cancer survivors: a systematic review and meta-analysisSupportive Care in Cancer, 2017